Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 690

1.

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F.

Lancet Neurol. 2012 Dec;11(12):1048-56. doi: 10.1016/S1474-4422(12)70228-4. Epub 2012 Nov 6.

2.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM.

Lancet Neurol. 2012 Dec;11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6.

3.

Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.

Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, Langbaum JB, Thiyyagura P, Fagan AM, Shah AR, Muniz M, Arboleda-Velasquez JF, Munoz C, Garcia G, Acosta-Baena N, Giraldo M, Tirado V, Ramírez DL, Tariot PN, Dickerson BC, Sperling RA, Lopera F, Reiman EM.

JAMA Neurol. 2015 Aug;72(8):912-9. doi: 10.1001/jamaneurol.2015.1099.

4.

Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, Langbaum JB, Roontiva A, Thiyyagura P, Lee W, Ayutyanont N, Lopez L, Moreno S, Muñoz C, Tirado V, Acosta-Baena N, Fagan AM, Giraldo M, Garcia G, Huentelman MJ, Tariot PN, Lopera F, Reiman EM.

JAMA Neurol. 2015 Mar;72(3):316-24. doi: 10.1001/jamaneurol.2014.3314.

5.

The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Ayutyanont N, Langbaum JB, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M, Ward M, Aguirre C, Acosta-Baena N, Madrigal L, Muñoz C, Tirado V, Moreno S, Tariot PN, Lopera F, Reiman EM.

J Clin Psychiatry. 2014 Jun;75(6):652-60. doi: 10.4088/JCP.13m08927. Review.

6.

PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.

Balasa M, Vidal-Piñeiro D, Lladó A, Antonell A, Bosch B, Castellanos F, Bargalló N, Bartres-Faz D, Molinuevo JL, Sánchez-Valle R.

J Alzheimers Dis. 2012;30(3):605-16. doi: 10.3233/JAD-2012-111949.

PMID:
22426017
7.

Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

Yau WY, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE.

Lancet Neurol. 2015 Aug;14(8):804-13. doi: 10.1016/S1474-4422(15)00135-0. Epub 2015 Jun 29.

8.

Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.

Thordardottir S, Ståhlbom AK, Ferreira D, Almkvist O, Westman E, Zetterberg H, Eriksdotter M, Blennow K, Graff C.

J Alzheimers Dis. 2015;43(4):1393-402. doi: 10.3233/JAD-140339.

PMID:
25182737
9.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
10.

Successful Scene Encoding in Presymptomatic Early-Onset Alzheimer's Disease.

Quiroz YT, Willment KC, Castrillon G, Muniz M, Lopera F, Budson A, Stern CE.

J Alzheimers Dis. 2015;47(4):955-64. doi: 10.3233/JAD-150214.

11.

Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R.

Cochrane Database Syst Rev. 2014 Jun 10;(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Review.

PMID:
24913723
12.

Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life.

Hausner L, Tschäpe JA, Schmitt HP, Hentschel F, Hartmann T, Frölich L.

Alzheimers Dement. 2014 Mar;10(2):e27-39. doi: 10.1016/j.jalz.2013.02.006. Epub 2013 Jul 11.

PMID:
23850332
13.

Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.

Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, Saldarriaga A, Lopera F.

Lancet Neurol. 2011 Mar;10(3):213-20. doi: 10.1016/S1474-4422(10)70323-9. Epub 2011 Feb 4.

PMID:
21296022
14.

CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.

Bendlin BB, Carlsson CM, Johnson SC, Zetterberg H, Blennow K, Willette AA, Okonkwo OC, Sodhi A, Ries ML, Birdsill AC, Alexander AL, Rowley HA, Puglielli L, Asthana S, Sager MA.

PLoS One. 2012;7(6):e37720. doi: 10.1371/journal.pone.0037720. Epub 2012 Jun 6.

15.

White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.

Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Ryan NS, Förster S, Laske C, Schofield PR, Sperling RA, Salloway S, Correia S, Jack C Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

Ann Neurol. 2016 Jun;79(6):929-39. doi: 10.1002/ana.24647. Epub 2016 Apr 27.

16.

Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years.

Mondadori CR, Buchmann A, Mustovic H, Schmidt CF, Boesiger P, Nitsch RM, Hock C, Streffer J, Henke K.

Brain. 2006 Nov;129(Pt 11):2908-22. Epub 2006 Sep 29.

PMID:
17012294
17.

Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.

Aguirre-Acevedo DC, Jaimes-Barragán F, Henao E, Tirado V, Muñoz C, Reiman EM, Tariot PN, Langbaum JB, Lopera F.

Int Psychogeriatr. 2016 Mar;28(3):503-10. doi: 10.1017/S1041610215001660. Epub 2015 Oct 19.

PMID:
26478578
18.

MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.

Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 Apr;132(Pt 4):1067-77. doi: 10.1093/brain/awp007. Epub 2009 Feb 27.

19.

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.

Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A.

Brain. 2016 Mar;139(Pt 3):922-36. doi: 10.1093/brain/awv404. Epub 2016 Jan 26.

20.

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2010 Mar;67(3):308-16. doi: 10.1002/ana.21953.

Supplemental Content

Support Center